Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-24-116839
Filing Date
2024-10-24
Accepted
2024-10-24 06:02:48
Documents
2
Period of Report
2024-10-21

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1542
2 EX-24 kytx-ex24.htm EX-24 12438
  Complete submission text file 0000950170-24-116839.txt   15446
Mailing Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608
Business Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608 5106268331
Kyverna Therapeutics, Inc. (Issuer) CIK: 0001994702 (see all company filings)

EIN.: 831365441 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O PAUL HASTINGS LLP 200 PARK AVENUE NEW YORK NY 10166
Business Address
Aktar Mert (Reporting) CIK: 0002040256 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-41947 | Film No.: 241390463